Literature DB >> 9090668

Lipoprotein glomerulopathy: a pediatric case report.

K Maruyama1, H Arai, T Ogawa, S Tomizawa, A Morikawa.   

Abstract

We report an 8-year-old girl with lipoprotein glomerulopathy who may have developed this condition as young as 4 years of age. To our knowledge this is the youngest reported case of this disease. Lipid studies of the patient and her family members revealed elevated concentrations of apolipoprotein E (apo E), the apo E phenotype E2/3, and the genotype E3/3. However, other families revealed no urinary abnormalities. Our findings suggest that an apo E abnormality may be responsible for the development of lipoprotein glomerulopathy. Genetic analysis of apo E is needed to clarify the pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090668     DOI: 10.1007/s004670050264

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  4 in total

1.  Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.

Authors:  Hiroko Hamatani; Keiju Hiromura; Keiko Kobatake; Hiroaki Yoshida; Satsuki Kobayashi; Naohiro Yoneda; Ken Kayakabe; Takayuki Matsumoto; Takashi Kuroiwa; Kazue Ueki; Yoshihisa Nojima
Journal:  Clin Exp Nephrol       Date:  2010-09-15       Impact factor: 2.801

2.  Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

Authors:  Akira Matsunaga; Masayuki Furuyama; Taeko Hashimoto; Kentaro Toyoda; Daisuke Ogino; Kiyoshi Hayasaka
Journal:  Clin Exp Nephrol       Date:  2009-07-15       Impact factor: 2.801

Review 3.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

4.  Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.

Authors:  Yunsi Li; Jin Chen; Yurong Zou; Wei Wang; Guisen Li
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.